Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are effective in the treatment of type 2 diabetes (T2D).[1,2] GLP-1RAs act as hypoglycemic agents while promoting weight loss through their effects on appetite and gastric emptying[3,4] and play a role in lowering glycated hemoglobin (HbA1c).[5] Dulaglutide is a subcutaneous GLP-1RA approved for monotherapy or as an add-on to other antihyperglycemic agents, including oral antihyperglycemic agents and insulin, in adults with T2D. Here, INS is linked to type 2 diabetes mellitus.